Beyett Lab

We are a molecular pharmacology lab primarily focused on kinases and kinase signaling in cancer. We utilize structural biology to understand molecular mechanisms of oncogenic activation and drug resistance and use this information to guide the development of novel chemical probes and inhibitors. We rely on high-throughput screening to identify lead molecules and rationally optimize them through structure-based drug design. These molecules serve as valuable tools for the validation of new drug targets, better study of pathophysiology, and exploration of novel therapeutic strategies. Our ultimate goal is to provide a foundation for the development of the next generation of cancer therapeutics.

We have expertise in protein biochemistry, structural biology (primarily X-ray crystallography), medicinal chemistry, chemical biology, and kinase pharmacology. Our membership in the Discovery and Developmental Therapeutics Program at the Winship Cancer Institute provides access to additional resources that allow us to translate promising chemical probes and inhibitors into real-world therapies.